Zosano Pharma Corp (NASDAQ:ZSAN) Spikes On Migraine Data
Zosano Pharma Corp (NASDAQ:ZSAN) traded higher after announcing the publication of positive pivotal data for its proprietary Adhesive Dermally-Applied Microarray technology. The stock was up by 5.6% in Thursday’s trading session, to end the day at $1.13 a share.
ZSAN Stock Performance
Shares of Zosano Pharma Corp (NASDAQ:ZSAN) are currently trading in a downtrend, after dropping from $3.50 a share in February. While the stock is slightly up for the year, it has underperformed the overall industry. Data compiled by Zacks Investment Research indicates that the stock is rated as a ‘buy,’ by one analyst firm and as a ‘hold’ by another.
Zosano Pharma Corp (NASDAQ:ZSAN) is a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its ADAM technology. The investigational technology platform is designed to offer rapid drug absorption into the bloodstream resulting in improved pharmacokinetic profile compared to other dosage forms.
A publication by Cephalalgia contains positive results from Zosano Pharma Corp (NASDAQ:ZSAN)’s Zotrip Pivotal study. The multicenter, double-blind randomized trial analyzed the safety and efficacy of ADAM Zolmitriptan for the treatment of acute migraine.
“We are pleased to have the results of ZOTRIP, our pivotal study, published in Cephalalgia. The recognition of the results from ZOTRIP in such a well-known journal will continue to raise awareness of M207, and its ability to address an unmet need for patients struggling to find rapid and durable pain relief for migraine episodes,” said CEO John P. Walker.
In addition to the publication, Zosano Pharma Corp (NASDAQ:ZSAN) has confirmed the appointment of Mr. Kenneth R. Greathouse to the board of directors. His experience in the field of neurology will be a key asset in bringing M207 to market.
He joins the company with over 40 years of experience in sales marketing and business development. Greathouse is also a co-founder of various pharmaceutical companies, including Manchester Pharmaceuticals.
“I look forward to working with the management team and Board as our lead program progresses towards an NDA filing and, if approved, towards commercialization,” said Mr. Greathouse.
Zosano Patent Application
Separately, Zosano Pharma Corp (NASDAQ:ZSAN) says it is in active discussions with the U.S Patent and Trademark Office (USPTO), regarding a patent application covering M207. The patent application details a method of rapidly achieving therapeutic concentrations of triptans for the treatment of migraines. If issued, the patent would extend coverage of the current patent from 2027 to 2037.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $ZSAN and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.